1,2,6-substituted benzimidazoles as flap modulators

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Janssen Pharmaceutica Nv patent solves the following problem:

Flap is a key initiator of the summary way leukotriene that bind and then move arachidonic acid into the 5-lipoxygenase (M. Abramovitz et al., 5-lipoxygenase-activating protein stimulates the use of arachidonic acid by 5 -lipoxygenase, Eur. J. Biochem., 1993, 215, 105-11). Flap shown to interact with the LTC4 synthase, and putatively modulate the production of LTC4 (T. Strid et al., Different parts of leukotriene C (4) synthase interact with the 5-lipoxygenase and 5-lipoxygenase activating protein, Biochem. Biophys. Res. Comm., 2009, 381 (4), 518-22). . Modulation (including without limitation restrictions) or the gene deletion flap block leukotriene production, particularly LTB4, cysteinyl leukotrienes (LTC4, LTD4 and LTE4) as well as 5-oxo-food (JZ Haeggstrm et al, lipoxygenase and leukotriene pathway : biochemistry, biology, and role in disease, Chem Rev., 2011, 111 (10), 5866-98).

Our analysis of this patent is as follows:

Janssen Pharmaceutica Nv’s patent US 9089569 B2 deals with 1,2,6-substituted benzimidazoles as flap modulators.
The present invention relates to compounds of Formula (I), and solvates, Refreshing, and pharmaceutically acceptable salts thereof, wherein X1, X1, X1, R1, R2 and P3 as described here, useful as modulators flap . The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) within the scope of the invention.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

RHAMM binding peptides

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The London Health Sciences Centre Research Inc. patent solves the following problem:

Throughout its application, various references cited in square brackets to describe more fully the state of the art that this invention relates.

Our analysis of this patent is as follows:

London Health Sciences Centre Research Inc.’s patent US 9090659 B2 deals with RHAMM binding peptides.
The present invention provides for a peptide that binds to the receptor for hyaluronic acid mediated motility (Rhamm) molecules. More specifically, the peptide could bind specifically Rhamm molecules can bind Rhamm with the largest high aunt. These novel Rhamm-binding peptide provide the basis for new imaging probes that can be used to identify cells expressing Rhamm, and for imaging procedures, prognosis, and treatment of conditions involved in Rhamm expression.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Anti-mucin antibodies for early detection and treatment of pancreatic cancer

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Immunomedics, Inc. patent solves the following problem:

This invention relates to anti-pancreatic cancer antibody and antigen-binding fragments thereof in pancreatic cancer mucin, preferably in a mucin selected from the group consisting of MUC1, MUC5ac and MUC16. More preferably, the antibody or fragment thereof bind with high selectivity for pancreatic cancer cells to allow the detection and / or diagnosis of pancreatic adenocarcinoma in the early stages of the disease. Most preferably, antibody-based assays are able to detect about 85% or more in pancreatic adenocarcinomas, with a false positive rate of about 5% or less for healthy controls. In particular embodiments, the methods and compositions can be used to identify and / or diagnose pancreatic adenocarcinoma with screening serum samples from subjects and the best way to detect 60% or more of the stage I pancreatic species cancer and 80% or more in stage II cancers through serum sample analysis. In some embodiments, ImmunoAssay with an anti-mucin antibody can be combined with immunodetection using other pancreatic cancer points, as CA19.9, providing better detection rates of pancreatic cancer have reduced specificity.

Our analysis of this patent is as follows:

Immunomedics, Inc.’s patent US 9089618 B2 deals with Anti-mucin antibodies for early detection and treatment of pancreatic cancer.
Described in these compositions and methods of using the anti-pancreatic cancer antibody or fragment thereof, such as murine, chimeric, humanized or human PAM4 antibody. The novel antibody display and useful diagnostic characteristics, like bind with high specificity to pancreatic and other cancers, but not in normal or benign pancreatic tissue sealing and a high percentage of early stage pancreatic cancers. Preferably, the antibody binds to pancreatic cancer mucins MUC1 or MUC5ac and use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibody can be used for ImmunoAssay serum sample, which ImmunoAssay detect a marker for early stage pancreatic cancer in serum. Most preferably, the serum obtained an organic part, such as butanol, before ImmunoAssay. On the other hand, ImmunoAssay with PAM4 and anti-CA19.9 antibody can be used to develop feelings for pancreatic cancer.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Antibodies that specifically bind to A beta oligomers and use thereof

File for Quick & Easy Patent Protection with PowerPatent.

The Immunas Pharma, Inc. patent solves the following problem:

The number of Alzheimer disease (AD) patients is more than 26 million worldwide in 2006, and is predicted to continue to increase in an aging society (Non-Patent Document 1) . However, there is no curative therapeutic agents to arrest or reverse the progress of Alzheimer's disease, although therapeutic agents that retard the progress of the disease are commercially available.

Our analysis of this patent is as follows:

Immunas Pharma, Inc.’s patent US 9090679 B2 deals with Antibodies that specifically bind to A beta oligomers and use thereof.
The present inventors successfully produced monoclonal antibody specific only melt a beta oligomers, but not to their melt with a beta monomers, which are physiological molecules. This indicates that the antibody is useful in diagnostic / therapeutic monoclonal antibody for Alzheimer's disease.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Gram-positive bacteria specific binding compounds

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Genentech, Inc. patent solves the following problem:

Program-positive microorganisms cause many systemic infections. An important member of the gram-positive pathogens are Staphylococcus aureus (S. aureus). 20% of the population is a long-term carrier of S. aureus. S. aureus can cause a range of illnesses from minor skin infections, such as pimples, impetigo (may also be caused by streptococcus pyogenes), boils, cellulitis folliculitis, furuncles, carbuncles, scalded skin syndrome and abscesses , life-threatening diseases such as pneumonia, meningitis, osteomyelitis, endocarditis, Toxic shock syndrome (TSS), and septicemia. S. aureus is capable of infecting all kinds of organs and tissues. S. aureus infection occur in immunocompetent as well as in immune compromised people. 50% of infections in US intensive unit care causing pathogen. Three hundred thousand S. aureus infections every year, resulting in 12,000 deaths, reported in the US (see also Moran et al. NEMJ 355, 666-674 (2006)).

Our analysis of this patent is as follows:

Genentech, Inc.’s patent US 9090677 B2 deals with Gram-positive bacteria specific binding compounds.
The present invention provides improved value compounds can specifically bind gram-positive bacteria. Binding compounds which are fully human, so that therapeutic applications of human individuals.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Monoclonal antibodies directed against the human immunodeficiency virus type 1 (hiv-1) P17 matrix (ma) protein

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Medestea Research & Production S.P.A. patent solves the following problem:

P17 protein known to play an important role in the pathogenesis of AIDS.

Our analysis of this patent is as follows:

Medestea Research & Production S.P.A.’s patent US 9090675 B2 deals with Monoclonal antibodies directed against the human immunodeficiency virus type 1 (hiv-1) P17 matrix (ma) protein.
Anti-HIV P17 monoclonal antibody described, which is capable of neutralizing the binding between the many HIV-1 P17 protein variants and p17R receptor given. Pharmaceutical compositions and methods of treatment using these antibody also given.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Rapid isolation of monoclonal antibodies from animals

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The The Board Of Regents Of The University Of Texas System patent solves the following problem:

The present invention relates generally to the field of antibody research and generation, and as antibody discovery from vaccinated animals. Especially, pertaining to novel methods and compositions for identifying and / or production of the desired antibody or antigen-binding fragment. It is also about recognizing the monoclonal antibody from any mammal and more generally any animal that has an adaptive immune response that leads to expression of soluble immunoglobulin and genomic information in the immunoglobulin locus is.

Our analysis of this patent is as follows:

The Board Of Regents Of The University Of Texas System’s patent US 9090674 B2 deals with Rapid isolation of monoclonal antibodies from animals.
Methods and compositions for identifying candidates antigen-specific variable region as well as the generation of the antibody or antigen-binding fragment desired antigen specificity given. For example, in some aspects of the methodology for determining the amino acid in the serum antibody CDR and abundancy described. In some aspects, the method for determining nucleic acid sequences of antibody variable region sequences and frequency given. Furthermore, the invention provides methods for the identification and generation of antibody or antigen-binding fragment comprising well-represented CDR.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Nucleic acids encoding desaturases and modified plant oil

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Basf Plant Science Gmbh, , Bioriginal Food & Science Corp. patent solves the following problem:

Our analysis of this patent is as follows:

Basf Plant Science Gmbh, , Bioriginal Food & Science Corp.’s patent US 9090902 B2 deals with Nucleic acids encoding desaturases and modified plant oil.
The present invention relates to nucleic acid derived from Drechslera tritici-repentis, Cylindorcarpon herteronema, Diploida natalensis, Stagonospora nodorum, Microdochium nivalae and Periplaneta americana. The invention also relates to the individual coding and combinations of proteins encoded by these sequences in combination with other ranges as well as a process for the conversion of oleic acid to linoleic acid Iinoleic acid and production of arachidonic acid, eicosapentaenoic acid and / or docosahexaenoic acid in a plant.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Dana-Farber Cancer Institute patent solves the following problem:

Targeted cancer therapy designed to disrupt the function of specific molecules needed for carcinogenesis and tumor growth and thus either kills or prevents the growth of cancer cells (Ji H et al (2006) Cell Cycle 5 (18 ): 2072-2076 Epub 2006 Sep. 15). Contrary to conventional cytotoxic chemotherapy, that target in cancer therapy may be more effective and less harmful to normal cells. A major effort to target cancer field therapy is to develop agents that target the skin growth factor receptor (EGFR). EGFR is a member of the erbB family of closely related receptor including EGFR (erbB-1), Her2 / Neu (erbB-2), Her3 (erbB-3) and Her4 (erbB-4 ). Activating EGFR leads to receptor tyrosine kinase activation and a series of lesser events signals that mediate cellular proliferation, motility, adhesion, invasion, and resistance to chemotherapy as well as inhibition of apoptosis (2-4), processes vital to the continual growth and survival of cancer cells.

Our analysis of this patent is as follows:

Dana-Farber Cancer Institute’s patent US 9090693 B2 deals with Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease.
The present invention relates to the treatment of EGFR-mediated diseases, especially cancer, which is resistant to tyrosine kinase inhibitor therapy. Methods for the treatment of cancer and reduction of tumor growth in individual secondary EGFR mutations, particularly tyrosine kinase domain mutations, resistant to standard therapy given. invention provides methods for the treatment of tyrosine kinase inhibitor resistant cancers with anti-EGFR antibody. Methods for the treatment of recurrent lung cancer, including non-small cell lung carcinoma that is resistant to tyrosine kinase inhibitor, with antibody anti-EGFR mAb806 described.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Interconnection wires of semiconductor devices

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Taiwan Semiconductor Manufacturing Company, Ltd. patent solves the following problem:

The semiconductor integrated circuit (IC) industry is experiencing exponential growth. IC technology materials and design, and technology nanometer being led to the generation of ICS where each generation is smaller and more complex circuits than any previous generation. In the course of IC evolution, functional density (ie, the number of interconnected devices per chip area) general increased while geometry size (ie, at least a component (or lines) that can be created using a fabrication process) declined. This process generally provides benefits by increasing production efficiency and lowering associated costs, but also increases the complexity of the processing and manufacturing ICs and molten challenges from the fabrication and design issues .

Our analysis of this patent is as follows:

Taiwan Semiconductor Manufacturing Company, Ltd.’s patent US 9093501 B2 deals with Interconnection wires of semiconductor devices.
A method of forming a semiconductor device includes forming a plurality of substantially equal-spaced first spacers with a first pitch on a substrate and forming the first metal interconnect wires using first spacers. method also includes forming a plurality of substantially equal-spaced second spacers in such a way Abut, respectively, the plurality of first metal interconnect wires and define a plurality of substantially equal-spaced canals. A plurality of second metal interconnect wires would, respectively, in the canal and the second spacers are removed, thus defining a plurality of substantially equal-spaced channels.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.